In recent years, research has focused on the immunoreactive components of the Sporothrix schenckii cell wall that can be relevant targets for preventive and therapeutic
vaccines against
sporotrichosis, an emergent worldwide mycosis. In a previous study, we identified a 47-kDa
enolase as an immunodominant
antigen in mice vaccinated with an adjuvanted mixture of S. schenckii cell wall
proteins. Here, we sought to assess the protective potential of a Sporothrix spp. recombinant
enolase (rSsEno) formulated with or without the adjuvant
Montanide Pet-GelA (
PGA) against the S. brasiliensis
infection in mice. Mice that were immunized with rSsEno plus
PGA showed increased antibody titters against rSsEno and increased median survival time when challenged with S. brasiliensis as compared with mice that had not been immunized or that were immunized with rSsEno alone. Immunization with rSsEno plus
PGA induced a predominantly T-helper 1
cytokine pattern after in vitro stimulation of splenic cells with rSsEno: elevated levels of IFN-γ and
IL-2, as well as of other
cytokines involved in host defense against
sporotrichosis, such as
TNF-alpha,
IL-6, and
IL-4. Furthermore, we show for the first time the presence of
enolase in the cell wall of both S. schenckii and S. brasiliensis. As a whole, our results suggest that
enolase could be used as a potential antigenic target for vaccinal purposes against
sporotrichosis.